Slower Deal-Making Year In Oncology Leaves Numerous Appealing Targets
Executive Summary
In terms of oncology alliances, 2009 is shaping up as slower than the previous three years, but the number of significantly priced deals has not decreased greatly
You may also be interested in...
With Geron Deal Done, AngioChem Turns To Its Own Pipeline
A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.
Rexahn Looks For Breakthrough Year With Three Clinical Candidates
Rexahn Pharmaceuticals hopes this will be its big year. With three candidates in various stages of Phase II development and cash projected to last through the first quarter of 2011, Rexahn feels it should be able to land at least one major deal to either co-develop or out-license one its lead programs
Rexahn Looks For Breakthrough Year With Three Clinical Candidates
Rexahn Pharmaceuticals hopes this will be its big year. With three candidates in various stages of Phase II development and cash projected to last through the first quarter of 2011, Rexahn feels it should be able to land at least one major deal to either co-develop or out-license one its lead programs